Adaptive Biotechnologies will announce Q2 2025 financial results on August 5, followed by a conference call and webcast.
Quiver AI Summary
Adaptive Biotechnologies Corporation announced it will release its second quarter 2025 financial results on August 5, 2025, after market close, followed by a conference call at 1:30 p.m. Pacific Time. The event will be webcast live and accessible via the company's website, with an archived replay available within 24 hours. The company focuses on leveraging the adaptive immune system for disease diagnosis and treatment, aiming to develop and commercialize tailored clinical products through its proprietary immune medicine platform. Their work spans two main areas: Minimal Residual Disease and Immune Medicine, targeting conditions like cancer and autoimmune disorders.
Potential Positives
- Announcement of Q2 2025 financial results provides transparency and insight into the company's performance to investors.
- Scheduled webcast and conference call offer an opportunity for investor engagement and direct communication from management.
- Emphasis on the proprietary immune medicine platform highlights the company's innovative approach and potential for significant advances in healthcare.
- Focus on individual patient solutions in its clinical pipeline demonstrates a commitment to personalized medicine, which is a growing trend in biotechnology.
Potential Negatives
- Adaptive Biotechnologies has not provided any specific financial guidance or expectations for the second quarter results, which may lead to uncertainty among investors about the company's performance.
- The announcement of the financial results reporting date comes without any earlier warning or interim updates on business performance, potentially signaling a lack of positive news to share.
- The press release lacks information on the company's development progress, leaving stakeholders with limited insights into the advancements of its clinical pipeline and any potential setbacks in projects.
FAQ
When will Adaptive Biotechnologies report its financial results?
Adaptive Biotechnologies will report its financial results for Q2 2025 on August 5, 2025, after market close.
How can I access the conference call about the financial results?
The conference call will be available via a webcast on the "Investors" section of the Adaptive Biotechnologies website.
What time is the financial results conference call scheduled?
The conference call will begin at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Will the webcast be available for replay?
Yes, the webcast will be archived and available for replay within 24 hours after the event.
What diseases does Adaptive Biotechnologies focus on diagnosing and treating?
Adaptive Biotechnologies focuses on diseases such as cancer and autoimmune disorders through its innovative immune medicine platform.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ADPT Insider Trading Activity
$ADPT insiders have traded $ADPT stock on the open market 27 times in the past 6 months. Of those trades, 0 have been purchases and 27 have been sales.
Here’s a breakdown of recent trading of $ADPT stock by insiders over the last 6 months:
- CHAD M ROBINS (CEO and Chairman) has made 0 purchases and 8 sales selling 975,124 shares for an estimated $7,996,870.
- HARLAN S ROBINS (Chief Scientific Officer) has made 0 purchases and 4 sales selling 166,766 shares for an estimated $1,193,329.
- JULIE RUBINSTEIN (President and COO) has made 0 purchases and 2 sales selling 59,505 shares for an estimated $415,539.
- ROBERT HERSHBERG sold 53,000 shares for an estimated $402,270
- MICHELLE RENEE GRIFFIN has made 0 purchases and 2 sales selling 51,955 shares for an estimated $385,304.
- SHARON BENZENO (Chief Commercial Ofc Imm Med) has made 0 purchases and 2 sales selling 44,665 shares for an estimated $311,792.
- SUSAN BOBULSKY (Chief Commercial Officer, MRD) sold 26,023 shares for an estimated $181,640
- FRANCIS LO (Chief People Officer) has made 0 purchases and 2 sales selling 20,875 shares for an estimated $145,845.
- KYLE PISKEL (Chief Financial Officer) has made 0 purchases and 4 sales selling 12,249 shares for an estimated $89,221.
- PETER M NEUPERT sold 10,000 shares for an estimated $70,500
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ADPT Hedge Fund Activity
We have seen 108 institutional investors add shares of $ADPT stock to their portfolio, and 93 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AMERIPRISE FINANCIAL INC added 5,905,756 shares (+801.6%) to their portfolio in Q1 2025, for an estimated $43,879,767
- BRAIDWELL LP added 4,803,794 shares (+inf%) to their portfolio in Q1 2025, for an estimated $35,692,189
- MILLENNIUM MANAGEMENT LLC removed 3,297,333 shares (-52.4%) from their portfolio in Q1 2025, for an estimated $24,499,184
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 2,973,142 shares (-99.7%) from their portfolio in Q1 2025, for an estimated $22,090,445
- IRON TRIANGLE PARTNERS LP added 2,134,061 shares (+inf%) to their portfolio in Q1 2025, for an estimated $15,856,073
- VICTORY CAPITAL MANAGEMENT INC added 1,746,571 shares (+9892.2%) to their portfolio in Q1 2025, for an estimated $12,977,022
- ARK INVESTMENT MANAGEMENT LLC removed 1,691,504 shares (-17.9%) from their portfolio in Q1 2025, for an estimated $12,567,874
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ADPT Analyst Ratings
Wall Street analysts have issued reports on $ADPT in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Craig-Hallum issued a "Buy" rating on 06/18/2025
- Piper Sandler issued a "Overweight" rating on 05/06/2025
- Goldman Sachs issued a "Buy" rating on 05/02/2025
- Scotiabank issued a "Sector Outperform" rating on 02/13/2025
To track analyst ratings and price targets for $ADPT, check out Quiver Quantitative's $ADPT forecast page.
$ADPT Price Targets
Multiple analysts have issued price targets for $ADPT recently. We have seen 5 analysts offer price targets for $ADPT in the last 6 months, with a median target of $12.0.
Here are some recent targets:
- John Wilkin from Craig-Hallum set a target price of $15.0 on 06/18/2025
- David Westenberg from Piper Sandler set a target price of $13.0 on 05/06/2025
- Tejas Savant from Morgan Stanley set a target price of $9.0 on 05/05/2025
- Salveen Richter from Goldman Sachs set a target price of $10.0 on 05/02/2025
- Sung Ji Nam from Scotiabank set a target price of $12.0 on 02/13/2025
Full Release
SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter 2025 after market close on Tuesday, August 5, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com . The webcast will be archived and available for replay within 24 hours after the event.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
[email protected]
ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
[email protected]
